1. Two-Drug Treatment Approaches in HIV: Finally Getting Somewhere?

   • Sean G. Kelly
   • Amesika N. Nyaku
   • Babafemi O. Taiwo

   Current Opinion 17 February 2016 Pages: 523 - 531

2. Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection

   • Denise C. Hsu
   • Irini Sereti

   Leading Article 25 February 2016 Pages: 533 - 549

   

3. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions

   • Paolo Curatolo
   • Marit Bjørnvold
   • Bernard A. Zonnenberg

   Therapy in Practice 29 February 2016 Pages: 551 - 565

   

4. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent

   • George G. Zhanel
   • Doris Cheung
   • James A. Karlowsky

   Review Article 10 February 2016 Pages: 567 - 588

   

5. Antipsychotic Management of Schizoaffective Disorder: A Review

   • Jean-Pierre Lindenmayer
   • Amandeep Kaur

   Review Article 29 February 2016 Pages: 589 - 604

   

6. Cobimetinib Plus Vemurafenib: A Review in BRAF ^V600 Mutation-Positive Unresectable or Metastatic Melanoma

   • Gillian M. Keating

   Adis Drug Evaluation 16 March 2016 Pages: 605 - 615

7. Elbasvir/Grazoprevir: First Global Approval

   • Gillian M. Keating

   AdisInsight Report 04 March 2016 Pages: 617 - 624

   

8. Comment on: “Therapies to Preserve β-Cell Function in Type 1 Diabetes”

   • Devi Dayal

   Letter to the Editor 15 March 2016 Pages: 625 - 626

9. Author’s Reply to Dayal: “Therapies to Preserve β-Cell Function in Type 1 Diabetes”

   • Johnny Ludvigsson

   Letter to the Editor 15 March 2016 Pages: 627 - 627